Spironolactone Plus Full-Dose ACE Inhibition in Patients With Idiopathic Membranous Nephropathy and Nephrotic Syndrome: Does It Really Work?

Pharmaceuticals - Switzerland
doi 10.3390/ph3010001

Related search